Serum Institute of India to resume trial for Oxford's COVID-19 vaccine candidate after DCGI nod
The trials were halted after AstraZeneca, the pharma company responsible for the vaccine, paused its UK trials after one of the volunteers developed a 'serious ailment'
Serum Institute of India will resume clinical trials of AstraZeneca's COVID-19 vaccine candidate after getting the permission from the Drugs Controller General of India (DCGI), the Pune-based vaccine maker said on Saturday.
Pharma giant AstraZeneca on Saturday said that clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that the trials were safe.
"Once DCGI will give us the permission to restart the trials in India, we will resume the trials," Serum Institute of India (SII) said in a statement.
In a tweet, SII CEO Adar Poonawalla said: "As I'd mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events is a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford."
The human trials resumed days after a pause had been announced in the trials after an adverse reaction in one of the participants.
Following the suspension, the DCGI directed Serum Institute of India to suspend till further orders new recruitment in phase 2 and 3 clinical trials of the vaccine candidate.
AstraZeneca and the University of Oxford, as the trial sponsor, on Saturday said that they cannot disclose further medical information but confirmed that independent investigations concluded that the trials were safe to restart.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
India surpasses US in global COVID-19 recoveries as tally exceeds 53 lakh; SII to begin phase III trials from Monday
Apart from the Oxford candidate, two more vaccine candidates in India are in advanced stages of clinical trials, while four are in pre-clinical development stage
Coronavirus Vaccine Tracker: Serum Institute of India pauses clinical trials after DCGI show-cause notice
The Pune-based company said that it's reviewing the situation and pausing India trials of the COVID-19 vaccine candidate till AstraZeneca restarts the trials
Coronavirus Updates: Kolkata Police Commissioner Anuj Sharma tests positive for COVID-19, says report
Coronavirus Updates: Lok Sabha Speaker Om Birla on Thursday also said that 62 percent of the Parliament's operations have been "successfully" moved online will go "100 percent digital eventually"